- Home
- TNXP vs PRME Comparison
TNXP vs PRME Comparison
Compare TNXP & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- PRME
- Stock Information
- Founded
- TNXP 2007
- PRME 2019
- Country
- TNXP United States
- PRME United States
- Employees
- TNXP N/A
- PRME N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- TNXP Health Care
- PRME Health Care
- Exchange
- TNXP Nasdaq
- PRME Nasdaq
- Market Cap
- TNXP 207.5M
- PRME 191.7M
- IPO Year
- TNXP N/A
- PRME 2022
- Fundamental
- Price
- TNXP $33.33
- PRME $2.07
- Analyst Decision
- TNXP Strong Buy
- PRME Buy
- Analyst Count
- TNXP 2
- PRME 6
- Target Price
- TNXP $585.00
- PRME $9.38
- AVG Volume (30 Days)
- TNXP 1.1M
- PRME 2.3M
- Earning Date
- TNXP 08-15-2025
- PRME 08-04-2025
- Dividend Yield
- TNXP N/A
- PRME N/A
- EPS Growth
- TNXP N/A
- PRME N/A
- EPS
- TNXP N/A
- PRME N/A
- Revenue
- TNXP $10,041,000.00
- PRME $3,846,000.00
- Revenue This Year
- TNXP $11.66
- PRME $104.12
- Revenue Next Year
- TNXP $793.18
- PRME $196.78
- P/E Ratio
- TNXP N/A
- PRME N/A
- Revenue Growth
- TNXP N/A
- PRME 550.76
- 52 Week Low
- TNXP $6.76
- PRME $1.11
- 52 Week High
- TNXP $137.25
- PRME $6.75
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- PRME 71.75
- Support Level
- TNXP $33.41
- PRME $1.56
- Resistance Level
- TNXP $37.42
- PRME $1.85
- Average True Range (ATR)
- TNXP 3.48
- PRME 0.19
- MACD
- TNXP -1.12
- PRME 0.07
- Stochastic Oscillator
- TNXP 33.66
- PRME 96.74
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.